Business Wire

Knopp Biosciences Appoints Mark Kreston as Chief Commercial Officer

Del

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced the appointment of pharmaceutical industry veteran Mark Kreston as its Chief Commercial Officer. Kreston has more than 30 years of experience with global pharmaceutical companies spanning all phases of commercialization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181206005127/en/

Mark Kreston, Chief Commercial Officer, Knopp Biosciences (Photo: Business Wire)

Mark Kreston, Chief Commercial Officer, Knopp Biosciences (Photo: Business Wire)

In his new role, Kreston will establish and execute global commercialization strategies and plans across the Knopp enterprise, with a particular focus on the Company’s lead program, dexpramipexole, an investigational drug candidate poised to enter Phase 3 trials in hypereosinophilic syndrome and Phase 2 trials in eosinophilic asthma. He will also be responsible for leading Knopp’s corporate strategy and business development activities, and will play a key role in the Company’s capital strategy.

“We are thrilled to welcome Mark to the Knopp team at this pivotal moment in our corporate development,” said Michael Bozik, M.D., Chief Executive Officer of Knopp. “His track record of launching major pharmaceutical products, including several blockbuster brands in the immunology sector, and his success in marketing oral products for conditions dominated by established biologics, will be invaluable as we advance dexpramipexole as a potential new treatment for eosinophil-associated diseases.”

Prior to joining Knopp, Kreston was corporate VP of Global Marketing, Inflammation & Immunology at Celgene, where he led the launch of Otezla for psoriasis. Before that, he served as worldwide VP of Global Marketing, Immunology at Johnson & Johnson, where he helped engineer global expansion of the company’s immunology business for Remicade and Stelara. Earlier, at Bristol-Myers Squibb, he was worldwide VP of Global Marketing, Immunology, responsible for launching Orencia for rheumatoid arthritis, and served as President of Consumer Medicines. Early in his career, he was product manager for Tylenol and Pepcid at McNeil Consumer Healthcare. Kreston holds a bachelor’s degree from the University of Pennsylvania and an MBA from the Cornell Johnson Graduate School of Management.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 clinical studies in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain. Please visit www.knoppbio.com.

Forward Looking Statement

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact information

ICR Healthcare
Media:
James Heins
Tel: +1 203 682 8251
Email: James.Heins@icrinc.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Dawex Raises €5 Million to Accelerate the Development of the Data Economy23.5.2019 06:45:00 CESTPressemelding

Dawex, a leading data exchange technology company and the operator of the largest data marketplace, today announced a new round of funding of €5 million with Amadeus (AMS.MC), Itochu Corporation (ITOCY), Bouygues Construction (BOUY.PA) and a French web entrepreneur entering Dawex’s capital, also joined by the historical investor Caisse des Dépôts (via its Banque des Territoires). Total funds raised from inception tops €12 million, including the recent €2.5M grant from Horizon 2020, the biggest European Union Research & Innovation program. Dawex co-founders Fabrice Tocco and Laurent Lafaye remain majority shareholders, retaining full control over the company’s strategy and operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005927/en/ With the rise of Artificial Intelligence, Internet of Things, and the emergence of Smart Cities, among other disruptive trends like the autonomous cars, huge quantities of valuable

TTS Pharma Limited Announces Closing of £10.3 Million Fundraising and New Board Appointment23.5.2019 06:00:00 CESTPressemelding

COMPLETION OF SERIES B FUNDRAISE TTS Pharma Limited (“TTS Pharma” or the “Company”), a UK company which is a vertically integrated supply chain manager in the cultivation, manufacturing and development of the emerging ethical cannabis market, announces that it has successfully closed a private equity investment totalling £10.3 million, on the basis of a two-tranche investment. This investment will permit TTS Pharma to become one of the leading global suppliers in this fast-growing multibillion-dollar industry, by allowing it to expand its existing supply chain, develop its own facilities and further strengthen its academic and commercial partnerships. It also enables the Company to advance its diversified operations in the wellness, nutraceutical and pharmaceutical sectors. The ethical cannabis market is set to become a high growth, disruptive and innovative new segment in the life sciences field and TTS Pharma is ideally positioned to capture rapid value within this market. BOARD UPDA

Buy and Sell Globally: 2019 Yiwu Imported Commodities Fair Opens in “World’s Capital of Small Commodities”23.5.2019 04:46:00 CESTPressemelding

On May 23-26, China Yiwu Imported Commodities Fair 2019 opened at Yiwu International Expo Center in Eastern China’s Yiwu city – the world’s capital of small commodities. The Fair of this year provides 2,012 standard booths in five halls, namely Asia I, Asia II, Europe, America-Australia-Africa & Cross-border Trade & Zhenjiang-International Sister Cities Exchange, and Imported Sweets and Wines, with an exhibition area of over 50,000m2 . Among the nearly 1,000 exhibitors from 85 countries and regions, 170 are from 40 countries and regions along the “Belt and Road” to exhibit daily necessities, home supplies, handicrafts, foods and drinks. Echoing China International Import Expo (CIIE), a special area is reserved for over 20 CIIE companies to exhibit their quality products including Bosch Group (Germany), skin care brand Rilastil (Italy), and Alligga (Canada) specializing in health products for a complete and balanced lifestyle. In addition, a special area for international sister cities

Lenovo Achieves Record Revenue for FY18/19 Driven by Success of Intelligent Transformation Strategy and Strong Operational Performance23.5.2019 04:27:00 CESTPressemelding

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced strong results delivering on the company’s Intelligent Transformation strategy and highlighting its leadership across all segments. For the first time, the global company delivered full-year revenue exceeding US$50 billion, up 12.5% to a record-breaking US$51 billion. The significant increase in profitability includes full-year pre-tax income up four and a half times (459%) year-on-year at US$856 million and net income at US$597 million, up US$786 million from negative US$189 million last year. The full-year performance included a notably strong fourth quarter characterized by improving revenue and profit across all businesses. Revenue grew by 10% year-on-year and reached US$11.7 billion. Pre-tax income was US$180 million, up almost four times year-on-year (US$143 million, +389%) and net income was US$118 million (up US$85 million, +261%). Basic earnings per share for the full year were 5.01 US cents or 39.2 HK cents, and f

The 26th HKTDC Hong Kong Fashion Week for Spring/Summer Opens in July23.5.2019 01:44:00 CESTPressemelding

The 26 th HKTDC Hong Kong Fashion Week for Spring/Summer will curtain up at the Hong Kong Convention and Exhibition Centre from 8-11 July 2019. The four-day fair is expected to welcome some 1,000 exhibitors from across the globe, presenting a wide array of spring/summer clothing, designers’ collections, international brands, garment and fabrics, and fashion accessories. As a premier sourcing platform for global buyers, the Hong Kong Fashion Week is also a gateway to vivacious markets of Mainland China and Asia, making it one of the must-attend global events in the fashion industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005901/en/ (Photo: Business Wire) Click HERE to Register for Your Free e-Badge Themed zones return with splendour The fashion industry has always been fast-paced, and with the adoption of technology, it has the capacity to change even faster and varied in greater extent. The fair has been keepin

Navico Goes Live with o9 Solutions Premier AI-driven Platform22.5.2019 18:38:00 CESTPressemelding

Navico has become one of the top clients for o9 Solutions in the consumer electronics industry by going live on o9’s Premier AI Platform for Integrated Planning and Digital Operations. Navico and o9 share a vision for connecting the ecosystems of technology and enabling its customers to make smarter decisions, faster, and free up more human interaction time for high-value and high-enjoyment activities. Navico is focused on creating the “Smart Boat” ecosystem, providing integration and connectivity of recreational boats for ease of use and maximum enjoyment by owners. Similarly, o9 is focused on creating a “Connected Enterprise,” where all of an organization’s processes and operations are modeled in a single dynamic Enterprise Knowledge Graph, enabling transformationally faster decision-making and value creation by leveraging the latest generation of artificial intelligence solutions. In the 2019 Gartner Magic Quadrant for Sales and Operations Planning Systems of Differentiation, o9 Sol